Cardiovascular Risks Associated with Diclofenac Use
Introduction to Anti-Inflammatory Drugs
Anti-inflammatory drugs are commonly used for quick pain relief but may carry serious risks. A comprehensive study conducted in Denmark analyzed the cardiovascular risks associated with diclofenac (Voltaren), a widely prescribed non-steroidal anti-inflammatory drug (NSAID), in comparison to other NSAIDs.
Background on Diclofenac
Diclofenac is available both by prescription and over the counter as Voltaren, serving to alleviate pain and reduce inflammation. Previous concerns over the cardiovascular risks associated with NSAIDs, such as rofecoxib, which was withdrawn from the market, have raised alarms about the safety of these medications.
Study Overview
To investigate the cardiovascular risks of diclofenac, researchers utilized data from Danish population-based health registries, emulating a clinical cohort study. The study included adults with a low risk of chronic diseases who sought medical attention and were prescribed diclofenac, ibuprofen, naproxen, or paracetamol from 1996 to 2016. For comparison, patients who sought medical care but were not prescribed any anti-inflammatories were also analyzed.
Study Findings
The researchers reviewed data from over 7 million patients, focusing on the incidence of adverse cardiovascular events within 30 days of starting therapy. These events encompassed irregular heartbeat, stroke, congestive heart failure, and heart attacks.
Increased Risk with Diclofenac
The study revealed that diclofenac may elevate the risk of adverse cardiovascular events by 50% compared to no therapy. When compared to other NSAIDs, diclofenac increased cardiovascular risk by 30% relative to naproxen and by 20% when compared with paracetamol and ibuprofen. Notably, the highest risk was observed in individuals with a history of heart conditions or diabetes. Additionally, diclofenac was linked to more than double the risk of gastrointestinal bleeding within 30 days compared to other anti-inflammatories and quadruple the risk compared to no therapy.
Recommendations for Diclofenac Use
In light of these findings, the study authors recommend that diclofenac be prescribed only by healthcare professionals. They advocate for increased awareness of its cardiovascular risks through warnings on packaging and suggest that safer NSAIDs be considered prior to initiating diclofenac therapy. These recommendations extend to clinical research, where diclofenac is often used as a reference drug in safety trials. The researchers propose low-dose ibuprofen as a safer alternative control drug for future studies.
Conclusion
This study underscores the importance of understanding the potential cardiovascular risks associated with diclofenac use, emphasizing the need for cautious prescribing practices and patient education.
References
Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018; 362: k3426. Published online 2018 Sep 4. doi: 10.1136/bmj.k3426.